Alzheimer's and Dementia

Top Research Topics at Alzheimers & Dementia?

The aim of the journal is to expand the discussion of research in Disease, Dementia, Internal medicine, Neuroscience and Gerontology. The journal holds forums on Disease that merges themes from other disciplines such as Genetics, Cognition and Immunology. It addresses concerns in Dementia which are intertwined with other disciplines, such as Psychiatry and Clinical psychology.

In addition to Internal medicine research, Alzheimers & Dementia aims to explore topics under Endocrinology, Oncology and Cardiology. Neuroscience research is the primary subject tackled in it with a focus on Neuroimaging. Alzheimers & Dementia features studies on Pathology, including topics such as Amyloid.

Many of the studies tackled connect Cognitive impairment with a similar field of study like Audiology.

• Disease (28.63%)
• Dementia (15.21%)
• Internal medicine (14.56%)

What are the most cited papers published in the journal?

• The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease (9970 citations)
• Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (4395 citations)
• 2016 Alzheimer's disease facts and figures (3990 citations)

Research areas of the most cited articles at Alzheimers & Dementia:

The most cited articles tackle a plethora of topics, such as Dementia, Disease, Alzheimer's disease, Internal medicine and Gerontology. The journal papers explore topics in Dementia which can be helpful for research in disciplines like Psychiatry, Cognition and Cohort study. The journal articles focus on Disease but sometimes tackle the closely related disciplines such as

• Neuroscience that intertwine with fields like Amyloid,
• Neuroimaging together with Alzheimer's Disease Neuroimaging Initiative..

What topics the last edition of the journal is best known for?

• Internal medicine
• Disease
• Gene

The previous edition focused in particular on these issues:

The discussions in the journal mainly cover the fields of Dementia, Disease, Internal medicine, Cognition and Amyloid beta. Topics in Dementia were tackled in line with various other fields like Confidence interval, Hazard ratio, Clinical trial and Gerontology. The studies in Disease featured incorporate elements of Biomarker (medicine) and Neuroscience.

The studies on Internal medicine discussed can also contribute to research in the domains of Endocrinology and Oncology. Clinical psychology, Audiology and Atrophy are some topics wherein Cognition research discussed in the journal have an impact. The presented Amyloid beta research focuses mostly on Cerebrospinal fluid and, on occasion, topics in Neurogranin.

The most cited articles from the last journal are:

• Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. (54 citations)
• The chronic neuropsychiatric sequelae of COVID-19: The need for a prospective study of viral impact on brain functioning. (28 citations)
• COVID-19 and dementia: Analyses of risk, disparity, and outcomes from electronic health records in the US. (27 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in Alzheimers & Dementia (based on the number of publications) are:

• Philip Scheltens (559 papers) published 5 papers at the last edition, 58 less than at the previous edition,
• Kaj Blennow (544 papers) published 21 papers at the last edition, 64 less than at the previous edition,
• Henrik Zetterberg (509 papers) published 20 papers at the last edition, 69 less than at the previous edition,
• Ronald C. Petersen (495 papers) published 8 papers at the last edition, 20 less than at the previous edition,
• Clifford R. Jack (484 papers) published 10 papers at the last edition, 25 less than at the previous edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in Alzheimers & Dementia (based on the number of publications) are:

• Mayo Clinic (1177 papers) published 21 papers at the last edition, 84 less than at the previous edition,
• University of California, San Francisco (993 papers) published 23 papers at the last edition, 149 less than at the previous edition,
• Harvard University (979 papers) published 22 papers at the last edition, 157 less than at the previous edition,
• University of Washington (718 papers) published 12 papers at the last edition, 80 less than at the previous edition,
• Karolinska Institutet (710 papers) published 22 papers at the last edition, 95 less than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 0.81% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 45.90% were posted by at least one author from the top 10 institutions publishing in the journal. Another 14.75% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 16.39% of all publications and 22.95% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Career Paths Related to Alzheimer's & Dementia Research

The field of Alzheimer's and dementia research is vast and offers numerous career opportunities. One of these is becoming a Speech-Language Pathologist, a professional who assists patients suffering from language and communication impairments - common issues experienced by those with dementia. These specialists utilize treatment strategies to enhance the communication skills of their patients. If you are interested in this path, find out more about how to become a speech therapist in Illinois. Another exciting career path in this field is to become a Clinical Psychologist. This profession involves diagnosing and treating the cognitive decline and mental health issues associated with Alzheimer's and dementia. They also provide emotional support to patients and their families as they navigate their journey with the disease. Moreover, professionals can venture into Internal Medicine, specializing in Geriatrics. These doctors manage the overall health of older adults, often dealing with patients with dementia. They play a vital role in diagnosing and managing Alzheimer's and other related diseases, making them an integral part of the healthcare team. Lastly, a rewarding career can be found in Neuroscience Research, where scientists study the brain's structure and function. They bring a deeper understanding of neurological disorders such as Alzheimer's, thereby contributing significantly to the development of treatment strategies. Regardless of which path you choose, each opportunity brings its own rewards and challenges, contributing significantly to the fight against Alzheimer's and dementia.